Video Experimental Relacionado
Updated: Aug 10, 2026
14:56
Sample Preparation to Bioinformatics Analysis of DNA Methylation: Association Strategy for Obesity and Related Trait Studies
Published on: May 6, 2022
Estrategias y posibles objetivos moleculares para el tratamiento de la obesidad
L A Campfield1, F J Smith, P Burn
1Department of Metabolic Diseases, Hoffmann-La Roche Incorporated, 340 Kingsland Street, Nutley, NJ 07110, USA. l_arthur.campfield@roche.com
Science (New York, N.Y.)
|June 20, 1998
Resumen
Mantener una pérdida de peso significativa es un desafío, pero una nueva investigación sobre la genética de la obesidad ofrece esperanza. La comprensión del equilibrio energético y la regulación de la masa grasa puede conducir a nuevos tratamientos farmacológicos para ayudar a controlar el peso.
Área de la Ciencia:
- Investigación de la obesidad.
- Genética La genética.
- El metabolismo es el metabolismo.
Sus antecedentes:
- La obesidad es un creciente problema de salud mundial.
- El mantenimiento a largo plazo de la pérdida de peso médicamente significativa (5-10%) es raro.
- La investigación sobre el balance energético y la regulación de la masa grasa ha aumentado desde 1995.
Objetivo del estudio:
- Revisar los avances en la comprensión de la obesidad.
- Identificar nuevos objetivos moleculares para el tratamiento de la obesidad.
- Explorar el papel de la genética en el equilibrio energético.
Principales métodos:
- Revisión de la literatura científica más reciente.
- Caracterización de los genes asociados a la obesidad.
- Análisis de las vías bioquímicas involucradas en la regulación de la masa grasa.
Principales resultados:
- Identificación de nuevas vías bioquímicas.
- Descubrimiento de posibles blancos moleculares para el desarrollo de fármacos.
- Mayor comprensión de la base genética de la obesidad.
Conclusiones:
- Las intervenciones farmacológicas dirigidas a vías identificadas son prometedoras.
- Es probable que los nuevos tratamientos complementen los cambios en el estilo de vida y el comportamiento.
- Los futuros tratamientos de la obesidad tienen como objetivo la pérdida de peso sostenida y la mejora de los resultados de salud.
Videos de Conceptos Relacionados
01:26Targets for Drug Action: Overview
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
01:24Obesity
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...